These findings highlight an epigenetic mechanism underlying LXRβ deficits linked to CIP, and LXRβ activation may represent a potential novel target for the treatment of CIP with an alteration in inflammation responses and synaptic transmission in ACC. This evidence concerns the gene NR1H2 and hereditary sensory and autonomic neuropathy.